Short answer
Xeris Biopharma Holdings, Inc. (XERS) filed an 8-K current report with the SEC on July 17, 2026 reporting Item 8.01 (Other Events). $23M of 8.00% convertible notes exchanged for approximately 5.0M shares and $23M cash.
Xeris Biopharma Holdings, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- $23M of 8.00% convertible notes exchanged for approximately 5.0M shares and $23M cash
- $10.5M of notes separately converted into approximately 3.6M shares
- All 2028 Notes due 2028 eliminated, removing future 8.00% interest and maturity obligations
- Cash consideration funded from on-hand liquidity, reducing cash while simplifying the capital structure
- Approximately 8.6M shares issued, creating dilution for existing shareholders; shares privately placed under Securities Act exemptions
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Xeris Biopharma Holdings, Inc. 8-K filings
Get the next XERS 8-K as it lands
Follow XERS for push alerts, or ask the research agent what this filing means.